OpenEvidence Review

No purchase order anywhere in this decision. OpenEvidence is free for NPI-verified clinicians, funded by advertising, and it never touches your budget. It reaches your medical staff regardless.

Viability isn't the worry here. They closed a $250 million Series D in January 2026 at a $12 billion valuation, and the licensed NEJM and JAMA corpus is a moat UpToDate has to take seriously. DeepConsult — their autonomous research agent — ships free to every verified U.S. clinician, and usage runs around 20 million consultations a month.

The catch: you're not the customer — pharma advertisers are, and the board should hear that framing before anyone blesses it. My call: sanction it now, write the ad-governance policy this quarter, and put a renewal-style review on the calendar for month 12.

A hallucinated dose recommendation is a patient-safety event, not a product bug, so provenance decides this entire evaluation. OpenEvidence pins every claim to inline citations across 300-plus journals, under licensed NEJM, JAMA, and NCCN content — licensed, not scraped, which is what I can defend to a P&T committee.

The long-term implication sits in Visits, the ambient-documentation layer: it moves the platform from lookup into the note itself, territory where health systems already hold scribing contracts with Abridge or Nuance DAX. Integration surface is the weak point — it runs beside Epic, not inside it, so every query is a separate pane of glass.

However, advertising funds the whole thing, and pharma promotion adjacent to clinical answers demands a formal conflict-of-interest policy before any system-wide endorsement. Write it now — with a reported 40% of U.S. physicians already using the platform daily, it's inside your walls either way.

A 500-physician system paying UpToDate list price spends about $290K a year on clinical lookup — $579 a seat, every seat, every year. OpenEvidence prices the identical job at $0. Ad-funded, NPI-verified, one plan, no tiers.

What's bundled matters more than the sticker. DeepConsult, their research agent, comes included; UpToDate sells nothing comparable, and Doximity GPT is free without the licensed journal corpus. CME credit accrues as physicians search — AMA PRA Category 1 — offsetting stipends you already pay.

But there's no contract, no SLA, no leverage. Advertising funds it today; a repricing to subscriptions later would find you with nothing in writing. Budget zero dollars and serious governance hours — the Visits documentation feature touches PHI, and that review is real work.

The real spec on the wards is the ninety seconds between patients, and cited search is the only feature that matters at that speed. A plain-language question — renal dosing, bridging anticoagulation, an ugly drug interaction — comes back synthesized, with each claim tappable through to the journal source.

The Lock Screen widget is the sleeper feature; rounding happens on a phone, and UpToDate's app was never built for that pace. DeepConsult covers the other mode — queue a hard question at sign-out and a report cross-referencing hundreds of studies lands within hours. Follow-up questions stay in one thread.

Nothing here lives inside Epic, but that's the real limitation — every lookup is a context switch out of the chart, and a Visits draft needs the same read-before-sign scrutiny as any scribe note. Free with AMA Category 1 CME attached — for daily inpatient questions, hard to beat.

Signing up wants your NPI number, not just an email, and that gate is quietly the whole point — everything inside assumes you're a clinician in a hurry. Past it, the product is a search box. No template gallery, no settings maze, nothing to configure.

The touches are right. A Lock Screen widget makes a lookup one tap, and Answer Update Alerts email you when new evidence changes something you asked months ago — the kind of feature nobody demos and everybody ends up loving. Doximity GPT is free too, but it never follows up on your old questions.

The tradeoff is the business model: ads pay for all of this, and ads have a way of getting louder as the years go by. For now it's free, hands out CME credit for reading, and over 750,000 U.S. physicians have signed on — tools this unfussy don't stay secret.

Eleven months took this valuation from $1 billion to $12 billion. Prices like that get paid for stories, and stories need endings that haven't been written yet. So: what's real?

More than I expected. NEJM, JAMA, and NCCN license content here — journals of that caliber don't sign with vaporware. Usage checks out too: a reported 1 million consultations in a single day by March 2026. And exit is painless; it's free, so you walk whenever.

The yellow flag is who pays. Pharma advertising sits under a clinical answer box, and that incentive deserves more sunlight than it gets. DeepConsult is genuinely differentiated — UpToDate has no answer for it — but if the ad model wobbles, 'free' is the first promise renegotiated.